Opinion|Videos|March 12, 2025
Understanding HER2 Testing in BTC: Detection and Clinical Approaches
Panelists discuss how molecular testing strategies at disease progression are evolving in biliary tract cancer (BTC), with particular focus on HER2-amplification detection methods including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), while noting that HER2 positivity occurs in approximately 5% to 15% of cases.
Advertisement
Episodes in this series
- Switching gears to BTC patients with disease progression requiring subsequent therapy, do you reperform biomarker testing at disease progression?
- How prevalent is HER2 amplification in BTC? How can HER2 amplification be detected and which techniques are you utilizing in your clinical practice (IHC, FISH, or NGS)?
- Please comment on any other important nuances to HER2 testing.
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
3
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens
4
Cutting-Edge Drug Shows Promise for Patients With NRAS-Driven Melanoma
5